Most mobilization regimens combine treatment with G-CSF (and rarely GM-CSF) after administration of a disease-specific chemotherapy regimen to achieve higher CD34+ cell yields than treatment with G-CSF alone, both in patients with MM and NHL (although failure rates with G-CSF plus chemotherapy seem to be as high as with G-CSF alone).3,11 For instance, Moskowitz et al.19 reported that mobilization with G-CSF alone (10 μg/kg daily) yielded 1.5 × 106/Kg CD34+ cells compared with 6.7 × 106/Kg CD34+ cells when chemotherapy plus G-CSF were used. The gene discussed is CD34; the disease is Miyoshi myopathy.